Skip to main content
FDA grants orphan drug designation to AstraZeneca's durvalumab
7/15/2019

AstraZeneca's Imfinzi, or durvalumab, received orphan drug designation from the FDA to treat small cell lung cancer. The drug resulted in statistically significant improvements in this patient population's overall survival.

Full Story: